QVAR® Is the Small-Particle ICS Available for Children as Young as 5 Years of Age3
Reaching the Small Airways is Important in Children4
- Inflammation in asthma is not confined to the large central airways but also extends to the small airways1,4
- A greater proportion of young children’s airways are classified as small4
The NAEPP Guidelines Recommend First-Line ICS Therapy in Children With Mild-to-Severe Persistent Asthma5
According to the most recent National Asthma Education and Prevention Program Guidelines (NAEPP, Expert Panel Report 3):
- “High-quality evidence demonstrates the effectiveness of ICS as initial therapy for children [5-11 years of age]
who have persistent asthma*5
QVAR® Reaches Deep Into the Lungs of Your Asthma Patients Age 5 and Older for Large and Small Airway Treatment6
- QVAR is a safe and effective treatment for children with asthma age 5 and over, with no Black Box warning3
- QVAR can be used with or without a spacer3
- QVAR’s lung deposition is consistent even when inhaler technique is poor, as is common in young children7*
- QVAR’s hydrofluoroalkane (HFA) propellant and solution formulation deliver smaller particle size1 and greater
lung deposition6†
- QVAR should be considered as a first-line choice for uncontrolled pediatric asthma patients because it
achieves consistently high lung deposition — distributed evenly thoughout the entire airway — while minimizing
deposition in the mouth and throat6
*This study used QVAR in the Autohaler device, which is not approved in the United States.
†The clinical efficacy of better lung deposition is unknown.
References:
- Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(2):S447-S460.
- Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;72:1016-1023.
- QVAR Prescribing Information, IVAX Laboratories Inc., 2008.
- Van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclomethasone dipropionate extrafine aerosol) in asthma (part 2): clinical experience in children. Int J Clin Pract. 2004;58(8):786-794.
- National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma—Full Report 2007. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; August 2007.
- Pedersen S, Warner J. Wahn U, et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics. 2002;109(6):e92
- Roller CM, Zhang G, Troedson RG, et al. Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children. Eur Respir J. 2007;29:299-306.
090650